For IPO Boutique's "scale of 1 to 5" BUY rating on Windward Bio Group AG, and our comprehensive analysis, click "Buy Market Research".
About Windward Bio Group AG (adapted from Windward Bio Group AG prospectus): They are a clinical-stage biotechnology company developing ultra-long-acting antibody medicines for patients with serious respiratory and dermatologic diseases, including asthma, chronic obstructive pulmonary disease, or COPD, and atopic dermatitis.
This description is adapted from prospectus. This description is not intended to be a recommendation to buy stock from this company. To see the company's full description, view their prospectus.
IPO Boutique aggregates information on public companies and private companies, such as "WWB" IPO, which is intended to educate our readers and help them evaluate potential investment opportunities and market conditions. We endeavor to research the financial industry and obtain independent verification of factual statements before presenting them to our users. Be informed.
Used our Comprehensive Single Promo Advisory and want more?
